Ascites News and Research

RSS

Prevention of primary variceal bleeding

Beta blockers should be the first line of prevention against variceal bleeding in patients with cirrhosis and portal hypertension. While banding is similarly effective in reducing the incidence of such bleeding, it can have fatal complications and is more expensive.

10 Sep 2007

Racial disparities in treatment of patients with cirrhosis and complications of portal hypertension

African-American and Hispanic patients hospitalized for complications of portal hypertension were less likely to undergo a palliative shunt, prompt endoscopy, or liver transplantation compared to white patients, according to a new study in the May issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD).

2 May 2007

Liver stiffness indicates severe portal hypertension in patients with hepatitis C-related cirrhosis

Measuring liver stiffness using transient elastography can predict severe portal hypertension in patients with hepatitis C-related cirrhosis, according to a new study in the May issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD).

2 May 2007

Gleevec available to patients in post-surgical GIST study

Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a major North American clinical trial after an interim analysis showed participants with Kit-positive gastrointestinal stromal tumors treated with Gleevec following surgery were significantly less likely to experience a return of their cancer compared to those not taking this innovative therapy.

15 Apr 2007

Cruelty-free ELISA for human insulin

In the January issue of Clinical Biochemistry, scientists and physicians with the Physicians Committee for Responsible Medicine (PCRM) outline the method used to develop a cruelty-free ELISA for human insulin that uses monoclonal antibodies produced by cells cultured in an animal-serum-free medium.

30 Jan 2007

WHO unveils new strategy to fight some of the most neglected tropical diseases

The World Health Organization (WHO) and a group of more than 25 partner organizations unveiled a new strategy to fight some of the most neglected tropical diseases that destroy the lives and health of poor people.

26 Oct 2006

Researchers identify potential ovarian cancer stem cells

Massachusetts General Hospital (MGH) researchers have identified potential ovarian cancer stem cells, which may be behind the difficulty of treating these tumors with standard chemotherapy.

21 Jul 2006

Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C

Cirrhosis related to non-alcoholic steatohepatitis (NASH) is associated with fewer complications and a lower mortality compared to cirrhosis from hepatitis C, despite NASH patients' greater risk of dying from cardiovascular events.

11 Apr 2006

Liver transplants may not be suitable for all cystic fibrosis patients

A new study on patients with cystic fibrosis (CF) who have had abnormal bleeding from ruptured blood vessels in the esophagus (variceal hemorrhage) as a result of liver disease found that transplant may not be indicated if there are no other indications of advanced liver disease.

5 Dec 2005

Discovery of mechanisms causing portal hypertension

A physician-scientist at UT Southwestern Medical Center and his research team have identified mechanisms causing a potentially deadly type of hypertension that results from liver damage – findings that could lead to its prevention.

3 Oct 2005

Psychosocial factors and interleukin-6 among women with advanced ovarian cancer

A new study funded by the National Cancer Institute reports that social support and other behavioral factors are related to levels of a circulating protein, which at high levels is associated with a poor prognosis in advanced ovarian cancer.

13 Jun 2005

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver, according to a recent study that compared the effects of celecoxib, naproxen, and a placebo on cirrhotic patients in a double-blind randomized controlled study.

22 Feb 2005

Severity of liver disease not a reliable indicator of quality of life

A new study on the determination of how livers are allocated for transplants examined the relationship between liver disease severity and quality of life, and found that the commonly used model for liver allocation is not a reliable indicator of general quality of life.

24 Jan 2005

Anemia is a major determinant of fatigue in patients with cirrhosis

Fatigue is a common complaint among patients with cirrhosis with many possible contributing factors, including severity of liver disease, anemia, and cardiopulmonary complications.

27 May 2004